Erschienen in:
01.06.2013 | Original Article
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin
verfasst von:
Yutaka Ueda, Takayuki Enomoto, Shinya Matsuzaki, Eiji Kobayashi, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Tateki Tsutsui, Tadashi Kimura
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 6/2013
Einloggen, um Zugang zu erhalten
Abstract
Purpose
The aim of the present study was to investigate, in ovarian carcinoma cases, the predictive association between the treatment-free interval (TFI) after an initial paclitaxel plus carboplatin (TC) therapy and the subsequent effectiveness of a second-line taxane-containing chemotherapy.
Methods
Patients with a TFI < 6 months from the first-line TC therapy were treated with a combination chemotherapy using docetaxel and irinotecan; patients with a TFI ≥ 6 months were retreated with the same regimen as the initial TC therapy. The clinical data of these patients were retrospectively analyzed for this study.
Results
The response rate of those with a TFI equal to 6–12 months was greater than that of those with a TFI < 6 months (p = 0.014) and less than that of those with a TFI > 12 months (p = 0.012). The progression-free survival of the cases with TFI equal to 6–12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0011). Overall survival of cases with a TFI equal to 6–12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0005).
Conclusions
The effectiveness of using a second-line taxane-containing chemotherapy was shown to be predictable by the TFI after the first-line taxane-containing chemotherapy, implying that the theory of ‘taxane-sensitivity’ may be applied for second-line chemotherapy in the same way as that of ‘platinum-sensitivity’.